Brain in Focus of Arterial Hypertension: Minimizing Negative Prognosis

Time codes:
  • 00:03:54

    Cognitive impairment is an early sign of brain damage in hypertension

  • 00:15:01

    Mini-Cog - dementia screening in 3-5 minutes at the appointment

  • 00:19:02

    Neuroprotection is necessary in case of cognitive impairment against the background of hypertension

  • 00:23:57

    Mexidol: a multimodal neuroprotector with proven efficacy

  • 00:25:01

    MEMO study: evidence base for the effectiveness of Mexidol in patients with hypertension

Tyrenko Vadim Vitalievich - Doctor of Medical Sciences, Professor, Head of the Department of Faculty Therapy of the S.M. Kirov Military Medical Academy, Chief Cardiologist of the Ministry of Defense of the Russian Federation, Chief Pulmonologist-Therapist of the Health Committee of the Government of St. Petersburg

 

 

 

Announcement:

The brain in focus of arterial hypertension: how to minimize the risk of cognitive impairment? For the attention of therapists, neurologists and general practitioners - a speech at a conference for primary care physicians from the head of the department of faculty therapy of the Kirov Military Medical Academy, chief cardiologist of the Ministry of Defense of the Russian Federation, chief freelance therapist-pulmonologist of the Health Committee of the Government of St. Petersburg, Vadim Vitalyevich Tyrenko , who will tell:

  • Why are cognitive impairments not a late complication, but the earliest sign of brain damage in hypertension?
  • Which current clinical guidelines already include assessment of cognitive function in patients with hypertension?
  • Which screening tests (Mini-Cog, MoCA, MMSE, clock drawing test) can realistically be used in a therapist's office visit - and how to interpret the results?
  • Why is blood pressure control not only about stroke prevention but also about protecting cognitive functions?
  • Which classes of antihypertensive drugs show a brain protective advantage?
  • Why is antihypertensive therapy alone not enough – and why is neuroprotection needed?

The report provides a detailed analysis of the MEMO study, which confirmed the effectiveness of the drug Mexidol in patients with chronic cerebral ischemia and arterial hypertension.

The drug is included in clinical guidelines for ischemic stroke and cognitive impairment in the elderly, and the resolution of the Expert Council emphasizes the need to include neuroprotection in the standard of care for patients with hypertension.

 Watch the full report to find out:

  • How to diagnose cognitive impairment at the earliest stages;
  • Why does memory suffer differently in vascular disorders than in Alzheimer's disease;
  • How to build a comprehensive strategy: from blood pressure control to neuroprotection.

The video lecture is a must-see for anyone who treats patients with hypertension, especially the elderly and those with polymorbidity.

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com